vs
Side-by-side financial comparison of ASTRONICS CORP (ATRO) and AVANOS MEDICAL, INC. (AVNS). Click either name above to swap in a different company.
ASTRONICS CORP is the larger business by last-quarter revenue ($240.1M vs $180.9M, roughly 1.3× AVANOS MEDICAL, INC.). On growth, ASTRONICS CORP posted the faster year-over-year revenue change (15.1% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $15.8M). Over the past eight quarters, ASTRONICS CORP's revenue compounded faster (13.9% CAGR vs 4.4%).
Astronics Corporation is an American aerospace electronics corporation founded in 1968, headquartered in East Aurora, New York. It is traded on NASDAQ as Nasdaq: ATRO. It is known for lighting and electronics integrations on military, commercial, and business aircraft and semiconductor test systems.
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
ATRO vs AVNS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $240.1M | $180.9M |
| Net Profit | — | $-1.3M |
| Gross Margin | 33.3% | 47.5% |
| Operating Margin | 14.8% | 1.4% |
| Net Margin | — | -0.7% |
| Revenue YoY | 15.1% | 0.7% |
| Net Profit YoY | — | 99.7% |
| EPS (diluted) | $0.82 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $240.1M | $180.9M | ||
| Q3 25 | $211.4M | $177.8M | ||
| Q2 25 | $204.7M | $175.0M | ||
| Q1 25 | $205.9M | $167.5M | ||
| Q4 24 | $208.5M | $179.6M | ||
| Q3 24 | $203.7M | $170.4M | ||
| Q2 24 | $198.1M | $171.7M | ||
| Q1 24 | $185.1M | $166.1M |
| Q4 25 | — | $-1.3M | ||
| Q3 25 | $-11.1M | $-1.4M | ||
| Q2 25 | $1.3M | $-76.8M | ||
| Q1 25 | $9.5M | $6.6M | ||
| Q4 24 | — | $-397.3M | ||
| Q3 24 | $-11.7M | $4.3M | ||
| Q2 24 | $1.5M | $1.8M | ||
| Q1 24 | $-3.2M | $-900.0K |
| Q4 25 | 33.3% | 47.5% | ||
| Q3 25 | 30.5% | 48.4% | ||
| Q2 25 | 25.8% | 52.6% | ||
| Q1 25 | 29.5% | 53.6% | ||
| Q4 24 | 29.8% | 54.6% | ||
| Q3 24 | 27.1% | 54.5% | ||
| Q2 24 | 28.0% | 55.7% | ||
| Q1 24 | 25.7% | 57.1% |
| Q4 25 | 14.8% | 1.4% | ||
| Q3 25 | 10.9% | 0.1% | ||
| Q2 25 | 2.3% | -42.6% | ||
| Q1 25 | 6.4% | 6.1% | ||
| Q4 24 | 4.3% | -233.0% | ||
| Q3 24 | 4.1% | 7.0% | ||
| Q2 24 | 3.8% | 3.7% | ||
| Q1 24 | 0.9% | 2.4% |
| Q4 25 | — | -0.7% | ||
| Q3 25 | -5.2% | -0.8% | ||
| Q2 25 | 0.6% | -43.9% | ||
| Q1 25 | 4.6% | 3.9% | ||
| Q4 24 | — | -221.2% | ||
| Q3 24 | -5.8% | 2.5% | ||
| Q2 24 | 0.8% | 1.0% | ||
| Q1 24 | -1.7% | -0.5% |
| Q4 25 | $0.82 | $-0.02 | ||
| Q3 25 | $-0.31 | $-0.03 | ||
| Q2 25 | $0.04 | $-1.66 | ||
| Q1 25 | $0.26 | $0.14 | ||
| Q4 24 | $-0.07 | $-8.64 | ||
| Q3 24 | $-0.34 | $0.09 | ||
| Q2 24 | $0.04 | $0.04 | ||
| Q1 24 | $-0.09 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.2M | $89.8M |
| Total DebtLower is stronger | — | $90.3M |
| Stockholders' EquityBook value | $140.1M | $778.2M |
| Total Assets | $706.7M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $89.8M | ||
| Q3 25 | $13.5M | $70.5M | ||
| Q2 25 | $13.5M | $90.3M | ||
| Q1 25 | $24.8M | $97.0M | ||
| Q4 24 | $9.3M | $107.7M | ||
| Q3 24 | $5.2M | $89.0M | ||
| Q2 24 | $2.9M | $92.2M | ||
| Q1 24 | $5.3M | $75.8M |
| Q4 25 | — | $90.3M | ||
| Q3 25 | — | $93.4M | ||
| Q2 25 | — | $95.7M | ||
| Q1 25 | — | $98.0M | ||
| Q4 24 | — | $125.3M | ||
| Q3 24 | — | $152.6M | ||
| Q2 24 | — | $164.9M | ||
| Q1 24 | — | $167.2M |
| Q4 25 | $140.1M | $778.2M | ||
| Q3 25 | $108.9M | $778.0M | ||
| Q2 25 | $271.6M | $776.3M | ||
| Q1 25 | $266.8M | $839.4M | ||
| Q4 24 | $256.1M | $828.5M | ||
| Q3 24 | $249.2M | $1.2B | ||
| Q2 24 | $257.9M | $1.2B | ||
| Q1 24 | $251.7M | $1.2B |
| Q4 25 | $706.7M | $1.1B | ||
| Q3 25 | $682.2M | $1.1B | ||
| Q2 25 | $646.7M | $1.0B | ||
| Q1 25 | $662.2M | $1.1B | ||
| Q4 24 | $648.8M | $1.2B | ||
| Q3 24 | $651.6M | $1.7B | ||
| Q2 24 | $644.9M | $1.7B | ||
| Q1 24 | $630.0M | $1.7B |
| Q4 25 | — | 0.12× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.13× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.6M | $28.2M |
| Free Cash FlowOCF − Capex | $15.8M | $21.3M |
| FCF MarginFCF / Revenue | 6.6% | 11.8% |
| Capex IntensityCapex / Revenue | 4.9% | 3.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $43.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.6M | $28.2M | ||
| Q3 25 | $34.2M | $14.0M | ||
| Q2 25 | $-7.6M | $6.8M | ||
| Q1 25 | $20.6M | $25.7M | ||
| Q4 24 | $26.4M | $57.9M | ||
| Q3 24 | $8.4M | $23.0M | ||
| Q2 24 | $-6.3M | $27.8M | ||
| Q1 24 | $2.0M | $-8.0M |
| Q4 25 | $15.8M | $21.3M | ||
| Q3 25 | $21.0M | $7.0M | ||
| Q2 25 | $-12.2M | $-4.2M | ||
| Q1 25 | $18.5M | $19.0M | ||
| Q4 24 | $23.2M | $53.1M | ||
| Q3 24 | $6.5M | $20.0M | ||
| Q2 24 | $-8.1M | $21.9M | ||
| Q1 24 | $439.0K | $-12.1M |
| Q4 25 | 6.6% | 11.8% | ||
| Q3 25 | 9.9% | 3.9% | ||
| Q2 25 | -6.0% | -2.4% | ||
| Q1 25 | 9.0% | 11.3% | ||
| Q4 24 | 11.1% | 29.6% | ||
| Q3 24 | 3.2% | 11.7% | ||
| Q2 24 | -4.1% | 12.8% | ||
| Q1 24 | 0.2% | -7.3% |
| Q4 25 | 4.9% | 3.8% | ||
| Q3 25 | 6.2% | 3.9% | ||
| Q2 25 | 2.2% | 6.3% | ||
| Q1 25 | 1.0% | 4.0% | ||
| Q4 24 | 1.5% | 2.7% | ||
| Q3 24 | 0.9% | 1.8% | ||
| Q2 24 | 0.9% | 3.4% | ||
| Q1 24 | 0.9% | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -5.81× | — | ||
| Q1 25 | 2.17× | 3.89× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 5.35× | ||
| Q2 24 | -4.08× | 15.44× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRO
| Product Line Electrical Power And Motion | $113.8M | 47% |
| Product Line Avionics | $32.0M | 13% |
| Military Aircraft | $28.0M | 12% |
| General Aviation | $22.3M | 9% |
| Government And Defense | $20.5M | 9% |
| Product Line Systems Certification | $13.2M | 6% |
| Product Line Structures | $3.7M | 2% |
| Product Line Other | $2.3M | 1% |
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
